ÀºÇòÅâÂÊ

ÀºÇòÅâÂÊ Services FAQ Contact Us 0
Home Healthcare IT Global Cancer Genetic Testing Market Size, Top Share, Forecast to 2033
Cancer Genetic Testing Market

Cancer Genetic Testing Market Size, Share & Trends Analysis Report By Type (Cytogenetic Testing/Chromosome Analysis, Biochemical Testing, Molecular Testing, DNA Sequencing), By Application (Lung Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Breast Cancer, Uterine Cancer), By End-Users (Hospitals and Clinics, Clinical Labs) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Report Code: SRHI1490DR
Author : Debashree Bora
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Cancer Genetic Testing Market Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Cytogenetic Testing/Chromosome Analysis
        1. By Value
      3. Biochemical Testing
        1. By Value
      4. Molecular Testing
        1. By Value
      5. DNA Sequencing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Lung Cancer
        1. By Value
      3. Cervical Cancer
        1. By Value
      4. Ovarian Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Breast Cancer
        1. By Value
      7. Uterine Cancer
        1. By Value
    4. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals and Clinics
        1. By Value
      3. Clinical Labs
        1. By Value
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Cytogenetic Testing/Chromosome Analysis
        1. By Value
      3. Biochemical Testing
        1. By Value
      4. Molecular Testing
        1. By Value
      5. DNA Sequencing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Lung Cancer
        1. By Value
      3. Cervical Cancer
        1. By Value
      4. Ovarian Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Breast Cancer
        1. By Value
      7. Uterine Cancer
        1. By Value
    4. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals and Clinics
        1. By Value
      3. Clinical Labs
        1. By Value
    5. U.S.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Cytogenetic Testing/Chromosome Analysis
          1. By Value
        3. Biochemical Testing
          1. By Value
        4. Molecular Testing
          1. By Value
        5. DNA Sequencing
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Lung Cancer
          1. By Value
        3. Cervical Cancer
          1. By Value
        4. Ovarian Cancer
          1. By Value
        5. Prostate Cancer
          1. By Value
        6. Breast Cancer
          1. By Value
        7. Uterine Cancer
          1. By Value
      3. By End-Users
        1. Introduction
          1. End-Users By Value
        2. Hospitals and Clinics
          1. By Value
        3. Clinical Labs
          1. By Value
    6. Canada
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Cytogenetic Testing/Chromosome Analysis
        1. By Value
      3. Biochemical Testing
        1. By Value
      4. Molecular Testing
        1. By Value
      5. DNA Sequencing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Lung Cancer
        1. By Value
      3. Cervical Cancer
        1. By Value
      4. Ovarian Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Breast Cancer
        1. By Value
      7. Uterine Cancer
        1. By Value
    4. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals and Clinics
        1. By Value
      3. Clinical Labs
        1. By Value
    5. U.K.
      1. By Type
        1. Introduction
          1. Type By Value
        2. Cytogenetic Testing/Chromosome Analysis
          1. By Value
        3. Biochemical Testing
          1. By Value
        4. Molecular Testing
          1. By Value
        5. DNA Sequencing
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Lung Cancer
          1. By Value
        3. Cervical Cancer
          1. By Value
        4. Ovarian Cancer
          1. By Value
        5. Prostate Cancer
          1. By Value
        6. Breast Cancer
          1. By Value
        7. Uterine Cancer
          1. By Value
      3. By End-Users
        1. Introduction
          1. End-Users By Value
        2. Hospitals and Clinics
          1. By Value
        3. Clinical Labs
          1. By Value
    6. Germany
    7. France
    8. Spain
    9. Italy
    10. Russia
    11. Nordic
    12. Benelux
    13. Rest of Europe
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Cytogenetic Testing/Chromosome Analysis
        1. By Value
      3. Biochemical Testing
        1. By Value
      4. Molecular Testing
        1. By Value
      5. DNA Sequencing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Lung Cancer
        1. By Value
      3. Cervical Cancer
        1. By Value
      4. Ovarian Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Breast Cancer
        1. By Value
      7. Uterine Cancer
        1. By Value
    4. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals and Clinics
        1. By Value
      3. Clinical Labs
        1. By Value
    5. China
      1. By Type
        1. Introduction
          1. Type By Value
        2. Cytogenetic Testing/Chromosome Analysis
          1. By Value
        3. Biochemical Testing
          1. By Value
        4. Molecular Testing
          1. By Value
        5. DNA Sequencing
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Lung Cancer
          1. By Value
        3. Cervical Cancer
          1. By Value
        4. Ovarian Cancer
          1. By Value
        5. Prostate Cancer
          1. By Value
        6. Breast Cancer
          1. By Value
        7. Uterine Cancer
          1. By Value
      3. By End-Users
        1. Introduction
          1. End-Users By Value
        2. Hospitals and Clinics
          1. By Value
        3. Clinical Labs
          1. By Value
    6. Korea
    7. Japan
    8. India
    9. Australia
    10. Singapore
    11. Taiwan
    12. South East Asia
    13. Rest of Asia-Pacific
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Cytogenetic Testing/Chromosome Analysis
        1. By Value
      3. Biochemical Testing
        1. By Value
      4. Molecular Testing
        1. By Value
      5. DNA Sequencing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Lung Cancer
        1. By Value
      3. Cervical Cancer
        1. By Value
      4. Ovarian Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Breast Cancer
        1. By Value
      7. Uterine Cancer
        1. By Value
    4. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals and Clinics
        1. By Value
      3. Clinical Labs
        1. By Value
    5. UAE
      1. By Type
        1. Introduction
          1. Type By Value
        2. Cytogenetic Testing/Chromosome Analysis
          1. By Value
        3. Biochemical Testing
          1. By Value
        4. Molecular Testing
          1. By Value
        5. DNA Sequencing
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Lung Cancer
          1. By Value
        3. Cervical Cancer
          1. By Value
        4. Ovarian Cancer
          1. By Value
        5. Prostate Cancer
          1. By Value
        6. Breast Cancer
          1. By Value
        7. Uterine Cancer
          1. By Value
      3. By End-Users
        1. Introduction
          1. End-Users By Value
        2. Hospitals and Clinics
          1. By Value
        3. Clinical Labs
          1. By Value
    6. Turkey
    7. Saudi Arabia
    8. South Africa
    9. Egypt
    10. Nigeria
    11. Rest of MEA
    1. Introduction
    2. By Type
      1. Introduction
        1. Type By Value
      2. Cytogenetic Testing/Chromosome Analysis
        1. By Value
      3. Biochemical Testing
        1. By Value
      4. Molecular Testing
        1. By Value
      5. DNA Sequencing
        1. By Value
    3. By Application
      1. Introduction
        1. Application By Value
      2. Lung Cancer
        1. By Value
      3. Cervical Cancer
        1. By Value
      4. Ovarian Cancer
        1. By Value
      5. Prostate Cancer
        1. By Value
      6. Breast Cancer
        1. By Value
      7. Uterine Cancer
        1. By Value
    4. By End-Users
      1. Introduction
        1. End-Users By Value
      2. Hospitals and Clinics
        1. By Value
      3. Clinical Labs
        1. By Value
    5. Brazil
      1. By Type
        1. Introduction
          1. Type By Value
        2. Cytogenetic Testing/Chromosome Analysis
          1. By Value
        3. Biochemical Testing
          1. By Value
        4. Molecular Testing
          1. By Value
        5. DNA Sequencing
          1. By Value
      2. By Application
        1. Introduction
          1. Application By Value
        2. Lung Cancer
          1. By Value
        3. Cervical Cancer
          1. By Value
        4. Ovarian Cancer
          1. By Value
        5. Prostate Cancer
          1. By Value
        6. Breast Cancer
          1. By Value
        7. Uterine Cancer
          1. By Value
      3. By End-Users
        1. Introduction
          1. End-Users By Value
        2. Hospitals and Clinics
          1. By Value
        3. Clinical Labs
          1. By Value
    6. Mexico
    7. Argentina
    8. Chile
    9. Colombia
    10. Rest of LATAM
    1. Cancer Genetic Testing Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Hoffmann-La Roche Ltd
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. QIAGEN N.V.
    3. Myriad Genetics, Inc.
    4. Abbott
    5. ThermoFisher Scientific, Inc.
    6. Illumina, Inc.
    7. Bio-Rad Laboratories, Inc
    8. Danaher
    9. PerkinElmer
    10. Agilent Technologies, Inc
    11. Quest Diagnostics
    12. Luminex Corporation
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Direct-to-Consumer Genetic Testing Market Size The global direct-to-consumer genetic testing market size was valued at USD 2.19 billion in 2024 and is expected to grow from USD 2.57 billion in 2025 to USD 9.20 billion by 2033, growing
Buy Now
Global Report
Genetic Testing Market Size The global genetic testing market size was valued at USD 19.73 Billion in 2024 and is projected to grow from USD 21.7 Billion in 2025 to reach USD 46.51 Billion by 2033, exhibiting a CAGR of 10% during the forecast period
Buy Now
Global Report
The global lung cancer genomic testing market size was valued at USD 1.21 billion in 2023. It is estimated to reach USD 2.47 billion by 2032, growing at a CAGR of 8% during the forecast period (2024–2032). In recent years, there has been an exp
Buy Now
Global Report
Rare Disease Genetic Testing Market Size The global rare disease genetic testing market size was valued at USD 1147.96 million in 2024 and is expected to grow from USD 1310.40 million in 2025 to reach USD 4.31 billion by 2033, growing at a CAGR
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

ÀºÇòÅâÂÊ
© Copyright . All rights Reserved.